Enhancing effect of chitosan on nasal absorption of salmon calcitonin in rats: comparison with hydroxypropyl- and dimethyl-β-cyclodextrins
Introduction
Salmon calcitonin (sCT) is an endogenous polypeptide hormone consisting of 32 amino acids which plays a vital role in both calcium homeostasis and bone remodeling. Nasal administration of sCT has been used therapeutically for the treatment of hypercalcemia, Paget’s disease, and osteoporosis (Stevenson and Evans, 1981, Jacobs, 1985). However, the relative bioavailability of sCT was reported to be poor, only 1.6% that of intramuscular preparation (Kagatani et al., 1996). To enhance the absorption efficacy of sCT, various enhancers have been investigated including bile salts, lauroylcarnitine chloride, and sodium tauro-24,25-dihydrofusidate (Kagatani et al., 1991, Kagatani et al., 1996, Lee et al., 1994). However, the use of these enhancers was often associated with some types of nasal membrane damages. For example, bile salts can induce significant release of several membrane components following nasal exposure in rats (Shao and Mitra, 1992). Other compounds reported to enhance the nasal absorption of peptides include laureth-9, lysophosphatidylcholine, and dimethyl-β-cyclodextrin (DM-β-CD; Gill et al., 1994, Shao et al., 1992, Merkus et al., 1991). However, all of these enhancers have been reported their membrane-irritating effect according to histology, ciliotoxicity, and membrane component release studies (Merkus et al., 1993, Marttin et al., 1995).
Chitosan is a cationic polysaccharide obtained from deacetylation of chitin, a structural polymer abundant in cretaceous animals like crabs and shrimps. Due to its biocompatibilty, biodegradability, and low toxicity, chitosan represents an attractive biopolymer for a variety of pharmaceutical applications (Illum, 1998, Paul and Sharma, 2000, Takahashi et al., 1990, Meshali and Gabr, 1993). Chitosans are potent absorption enhancers for poorly absorbed hydrophilic drugs. They improve, for example, the uptake of polypeptides such as atenolol, insulin, and buserelin across nasal and intestinal epithelia (Schipper et al., 1997, Illum et al., 1994, Luessen et al., 1996). The mechanism of action was suggested to be a combination of mucoadhesion (Henriksen et al., 1996, Witschi and Mrsny, 1999) an effect on the gating properties of the tight junction (Artursson et al., 1994, Illum et al., 1994).
In our previous work, we compared the absorption enhancing activity and safety of different types of chitosan with that of DM-β-CD and hydroxypropyl-β-cyclodextrin (HP-β-CD) using in situ rat nasal perfusion techniques (Tengamnuay et al., 2000). We found that both the free amine and soluble salt forms of chitosans were effective nasal absorption enhancers of l-Tyr-d-Arg, a model opioid dipeptide. The more soluble salt form appeared to be less dependent on pH whereas the enhancing activity of the free amine chitosan increased as the pH was lowered from 6 to 4. We also found that both chitosans had a relatively mild effect on the rat nasal membrane. The extent of total protein, phosphorus, and lactate dehydrogenase (LDH) release after nasal perfusion with chitosans (0.1 and 0.5%) was low and much less than that induced by 1.25 and 5% DM-β-CD, an effective enhancer reported to have marked membrane-irritating effects (Muangkum and Tengamnuay, 1999, Krishnamoorthy et al., 1995, Marttin et al., 1995, Yoshida et al., 1988). Despite the promising potential of chitosan as a safe and effective nasal absorption enhancer, studies to confirm its in vivo efficacy are limited. Also, its in vivo enhancing activity relative to other commonly studied enhancers has not been extensively investigated.
Thus, the primary purpose of this study was to evaluate the in vivo efficacy of chitosan as a nasal absorption enhancer of sCT in rat. Changes in plasma calcium (hypocalcemic effect) and sCT levels were used as indicators of sCT absorption. The effects of chitosan type, pH, and concentration were investigated and results were subsequently compared with that of DM-β-CD and HP-β-CD.
Section snippets
Chemicals
Chitosan free amine (CS J) with viscosity average molecular weight (MWv) of 1860 kDa and 80% deacetylation was purchased from Kyowa Technos Co. (Japan). Chitosan glutamate (CS G) (Seacure G 210+, MWv 800 kDa and >70% deacetylated) was donated by Pronova Biopolymer (Norway). The actual molecular weight of the chitosan content in CS G approximately 480 kDa taken into account of the 35–45% presence of glutamic acid in the CS G. Salmon calcitonin, synthetic (sCT) was purchased from Sigma Chemicals Co.
Effect of pH of chitosan on in vivo nasal absorption enhancing efficacy
The enhancing activity of both chitosans appear to depend on pH. The enhancing effect of CS J was observed to increase as the pH is decreased (Fig. 2a). This could be due to the ability of the free amine form which require an acidic condition for ionization and hydration. Chitosan is a basic polymer with an intrinsic pKa value of about 6.5 (Schipper et al., 1996). As the pH is lowered below its pKa, the fraction of the ionized groups in the chitosan molecules increases. However, too acidic pH
Conclusion
The in vivo absorption data indicated the potential of CS J and CS G as effective nasal absorption enhancers of peptides like sCT. Their enhancing effects were equivalent to β-cyclodextrins, particularly 1% CS J which exhibited strong activity comparable to 5% DM-β-CD under their corresponding optimum pH. However, our previous study found that DM-β-CD was more irritating to the rat nasal mucosa than CS J and CS G (Tengamnuay et al., 2000). Perfusion of the rat nasal cavity with 1.25% DM-β-CD
Acknowledgements
This project was supported by a grant from the Rachadapisek Research Fund of Chulalongkorn University, Bangkok, Thailand.
References (33)
- et al.
Bioadhesion of hydrated chitosans: an in vitro and in vivo study
Int. J. Pharm.
(1996) - et al.
Absorption enhancers in nasal drug delivery: efficacy and safety
J. Control. Release
(1993) - et al.
Cyclodextrins in nasal drug delivery
Adv. Drug Del. Rev.
(1999) - et al.
Effects of interpolymer complex formation of chitosan with pectin or acacia on the release behavior of chlorpromazine HCl
Int. J. Pharm.
(1993) - et al.
Screening of cationic compounds as an absorption enhancer for nasal drug delivery
Int. J. Pharm.
(1999) - et al.
Effect of dose, pH and osmolarity on nasal absorption of secretin in rats
J. Pharm. Sci.
(1985) - et al.
Effect of dose, pH and osmolarity on nasal absorption of secretin in rats: II. Histological aspects of the nasal mucosa in relation to the absorption variation due to the effects of pH and osmolarity
J. Pharm. Sci.
(1987) - et al.
Characteristics of polyanion complexes of chitosan with sodium alginate and sodium polyacrylate
Int. J. Pharm.
(1990) - et al.
Chitosans as nasal absorption enhancers of peptides: comparison between free amine chitosans and soluble salts
Int. J. Pharm.
(2000) - et al.
The potential of cyclodextrins as absorption enhancers in nasal delivery of peptide drugs
J. Control. Release
(1994)
Pharmaceutical evaluation of hydroxyalkyl ethers of β-cyclodextrins
Int. J. Pharm.
Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (Caco-2)
Pharm. Res.
Cyclodextrins as protection agents against enhancer damage in nasal delivery systems. 2. Effect on in-vivo absorption of insulin and histopathology of nasal membrane
Eur. J. Pharm. Sci.
Absorption of drugs from the nasal mucosa of rat
Int. J. Pharm.
Chitosan and its use as a phamaceutical excipient
Pharm. Res.
Chitosan as a novel nasal delivery system for peptide drugs
Pharm. Res.
Cited by (115)
Airway epithelial-targeted nanoparticle reverses asthma in inhalation therapy
2024, Journal of Controlled ReleaseDevelopment and optimization of chitosan coated nanoemulgel of telmisartan for intranasal delivery: A comparative study
2021, Journal of Drug Delivery Science and TechnologyAdvanced formulations for intranasal delivery of biologics
2018, International Journal of PharmaceuticsAdministration Routes for Nano Drugs and Characterization of Nano Drug Loading
2018, Characterization and Biology of Nanomaterials for Drug Delivery: Nanoscience and Nanotechnology in Drug DeliveryRole of butter oil in brain targeted delivery of Quetiapine fumarate microemulsion via intranasal route
2017, Journal of Drug Delivery Science and TechnologyCitation Excerpt :However, the precise mechanism of their action is not known but they may work by a different mechanism like increasing membrane fluidity, expanding the dimension of the paracellular pathway to solute transport, creating transient pores by reverse micelle formation in the cell membrane or combination of more than one mechanism [7]. The approval of a permeation enhancer is not only given based on its ability to enhance absorption but also on its overall safety profile with respect to both local and systemic effects [8]. In the current proposal, we have used butter oil (BO) of cow origin as a novel lipidic permeation enhancer.
Formulation optimization of scutellarin-loaded HP-β-CD/chitosan nanoparticles using response surface methodology with Box–Behnken design
2017, Asian Journal of Pharmaceutical Sciences